Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.

Reif A., ANIL YAĞCIOĞLU A. E., Luts A., Messer T., Nielsen R., Buyze J., ...More

31st European Congress of Psychiatry (EPA), Paris, France, 25 March 2023

  • Publication Type: Conference Paper / Summary Text
  • City: Paris
  • Country: France
  • Hacettepe University Affiliated: Yes